비용종을 동반한 만성 비부비동염의 치료로서 생물학적 제제의 효과

키워드

참고문헌 (37)

1. Lourijsen ES, "Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps : a multicentre, randomised, controlled trial", Lancet Respir Med, 10(4), pp.337~346 (2022)
2. Loftus CA, "Revision surgery rates in chronic rhinosinusitis with nasal polyps : meta-analysis of risk factors", Int Forum Allergy Rhinol, 10(2), pp.199~207 (2020)
3. Kamath AV, "Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies", Drug Discov Today Technol, 21-22, pp.75~83 (2016)
4. Dua P, "A tutorial on target-mediated drug disposition(TMDD)models", CPT Pharmacometrics Syst Pharmacol, 4(6), pp.324~337 (2015)
5. Bachert C, "Biologics for chronic rhinosinusitis with nasal polyps", J Allergy Clin Immunol, 145(3), pp.725~739 (2020)
6. Fokkens WJ, "Executive summary of EPOS 2020including integrated care pathways", Rhinology, 58(2), pp.82~111 (2020)
7. Kaur D, "Mast cells express IL-13Rα1 : IL-13 promotes human lung mast cell proliferation and FcɛRI expression", Allergy, 61(9), pp.1047~1053 (2006)
8. Bachert C, "EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps(CRSwNP)and biologics : definitions and management", J Allergy Clin Immunol, 147(1), pp.29~36 (2021)
9. Liu LY, "Decreased expression of membrane IL-5receptor α on human eosinophils : II. IL-5 down-modulates its receptor via a proteinase-mediated process", J Immunol, 169(11), pp.6459~6466 (2002)
10. Takabayashi T, "Formation of nasal polyps : the roles of innate type 2 inflammation and deposition of fibrin", J Allergy Clin Immunol, 145(3), pp.740~750 (2020)
11. Jonstam K, "Dupilumab reduces local type 2pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis", Allergy, 74(4), pp.743~752 (2019)
12. Magee C, "Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis : a systematic review", Ther Adv Musculoskelet Dis, 13, pp.1759720~ (2021)
13. Numata T, "Effectiveness of switching biologics for severe asthma patients in Japan : a single-center retrospective study", J Asthma Allergy, 14, pp.609~618 (2021)
14. McCracken JL, "Biologic therapy in the management of asthma", Curr Opin Allergy Clin Immunol, 16(4), pp.375~382 (2016)
15. Bachert C, "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis : a randomized clinical trial", JAMA, 315(5), pp.469~479 (2016)
16. Bachert C, "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials", Lancet, 394(10209), pp.1638~1650 (2019)
17. Laidlaw TM, "Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD", J Allergy Clin Immunol Pract, 7(7), pp.2462~2465 (2019)
18. Orlandi RR, "International consensus statement on allergy and rhinology : rhinosinusitis 2021", Int Forum Allergy Rhinol, 11(3), pp.213~739 (2021)
19. Gevaert P, "Efficacy and safety of omalizumab in nasal polyposis : 2 randomized phase 3 trials", J Allergy Clin Immunol, 146(3), pp.595~605 (2020)
20. Gevaert P, "Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma", J Allergy Clin Immunol, 131(1), pp.110~116 (2013)
21. Namazy J, "The Xolair Pregnancy Registry(EXPECT) : the safety of omalizumab use during pregnancy", J Allergy Clin Immunol, 135(2), pp.407~412 (2015)
22. Gevaert P, "Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis", J Allergy Clin Immunol, 128(5), pp.989~995 (2011)
23. Bachert C, "Reduced need for surgery in severe nasal polyposis with mepolizumab : randomized trial", J Allergy Clin Immunol, 140(4), pp.1024~1031 (2017)
24. Han JK, "Mepolizumab for chronic rhinosinusitis with nasal polyps(SYNAPSE) : a randomised, double-blind, placebo-controlled, phase 3trial", Lancet Respir Med, 9(10), pp.1141~1153 (2021)
25. Tuttle KL, "A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease", J Allergy Clin Immunol Pract, 6(3), pp.1045~1047 (2018)
26. Mi-Kyeong Kim, "Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies", The Korean Journal of Internal Medicine, 36(2), pp.362~370 (2021), 대한내과학회[DOI]
27. Gevaert P, "Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps", J Allergy Clin Immunol, 118(5), pp.1133~1141 (2006)
28. Bachert C, "Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps : a randomized, placebo-controlled trial", J Allergy Clin Immunol, 149(4), pp.1309~1317 (2022)
29. Peters AT, "Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps", J Allergy Clin Immunol Pract, 9(6), pp.2461~2471 (2021)
30. Oykhman P, "Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis : a systematic review and network meta-analysis", J Allergy Clin Immunol, 149(4), pp.1286~1295 (2022)
31. Busse WW, "Holy Grail : the journey towards disease modification in asthma", Eur Respir Rev, 31(163), pp.210183~ (2022)
32. Wechsler M, "P219 dupilumab is well tolerated and shows sustained efficacy in patients with asthma : liberty asthma traverse", Ann Allergy Asthma Immunol, 125(Suppl 5), pp.S33~ (2020)
33. Nopp A, "After 6 years with Xolair; a 3-year withdrawal follow-up", Allergy, 65(1), pp.56~60 (2010)
34. Molimard M, "Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control", Respir Med, 108(4), pp.571~576 (2014)
35. Gevaert P, "Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study", J Allergy Clin Immunol, 149(3), pp.957~965 (2022)
36. Sandström T, "Omalizumab in the management of patients with allergic(IgE-mediated)asthma", J Asthma Allergy, 2, pp.49~62 (2009)
37. Zhu R, "Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps", Pulm Pharmacol Ther, 71, pp.102080~ (2021)

관련 논문AI추천